Northern Trust’s Processa Pharmaceuticals PCSA Stock Holding History

Northern Trust’s Portfolio PCSA Stock Details PCSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-56	Closed	-$9.41K	–	4463
2023 Q4	$9.41K	Buy	56 +25	+81%	+$5.58K	﹤0.01%	4423
2023 Q3	$3.85K	Hold	31	–	–	﹤0.01%	4448
2023 Q2	$7.66K	Hold	31	–	–	﹤0.01%	4493
2023 Q1	$7.7K	Hold	31	–	–	﹤0.01%	4544
2022 Q4	$16.9K	Hold	31	–	–	﹤0.01%	4517
2022 Q3	$35K	Hold	31	–	–	﹤0.01%	4420
2022 Q2	$43K	Hold	31	–	–	﹤0.01%	4448
2022 Q1	$46K	Hold	31	–	–	﹤0.01%	4547
2021 Q4	$75K	Hold	31	–	–	﹤0.01%	4506
2021 Q3	$132K	Buy	31 +5	+19%	+$17.1K	﹤0.01%	4329
2021 Q2	$105K	Hold	26	–	–	﹤0.01%	4353
2021 Q1	$140K	Buy	+26	New	+$121K	﹤0.01%	4207

Other funds holding PCSA

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

MSG

Main Street Group Glen Allen, Virginia $429M AUM 34.03% 1-Year Est. Return

Allworth Financial Folsom, California $24.7B AUM 15.55% 1-Year Est. Return

MIM

Macroview Investment Management Bethesda, Maryland $144M AUM 19.29% 1-Year Est. Return

Northern Trust's PCSA Position: Q1 2024 in Review

Northern Trust sold out of Processa Pharmaceuticals (PCSA) in Q1 2024, closing a stake of 56 shares — an estimated $9.41K sold.

Northern Trust first reported a position in PCSA in Q1 2021 and held it in 12 quarters. The position peaked at $140K in Q1 2021. 9 funds tracked by Wall St. Rank hold PCSA as of Q1 2024.

Northern Trust reported no remaining Processa Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Northern Trust sold 56 Processa Pharmaceuticals shares in Q1 2024, an estimated $9.41K.
Northern Trust first reported a position in Processa Pharmaceuticals in Q1 2021 and held it in 12 quarters.
Northern Trust's Processa Pharmaceuticals position peaked at $140K in Q1 2021.
9 funds tracked by Wall St. Rank held Processa Pharmaceuticals as of Q1 2024.

Based on Northern Trust's 13F filing for Q1 2024, filed 14 May 2024.